ESMO 2020 | Designing Phase II trials for LMS using PFS as primary endpoint: a STBSG meta-analysis

Georgios Kantidakis, BSc, MSc, Fellow statistician, EORTC Headquarters, Brussels, Belgium, identifies unmet needs in the treatment of soft tissue sarcomas, specifically leiomysarcoma (LMS). He outlines a meta-analysis study which aims to provide new thresholds for designing studies for advanced or metastatic LMS. Data has been gathered from previous studies and is currently being requested from primary investigators. He hopes that new Phase II studies in LMS treatment will arise following study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).